
zzso is a novel agent that zzso zzso zzso 1 and 2 zzso and zzso The primary objective of this phase I study was to investigate the safety and zzso of zzso when administered as zzso to patients with solid zzso 

zzso patients with advanced zzso were treated at doses of zzso zzso once daily zzso and zzso zzso zzso 

zzso zzso analysis revealed rapid zzso and elimination with minimal zzso after repeated zzso or zzso zzso Exposure increased in a zzso manner from zzso zzso zzso plasma concentration zzso was attained zzso hour after dose, and zzso was zzso zzso zzso analysis of circulating zzso demonstrated maximum zzso zzso zzso zzso 1-2 hours after dose, zzso with zzso and greater zzso zzso at higher zzso The average zzso zzso in zzso at the highest dose tested, 70 zzso zzso was zzso zzso zzso zzso at zzso drug zzso zzso zzso zzso consisted of zzso zzso adverse events zzso including zzso anxiety, zzso memory loss, hallucinations, and behavior zzso These zzso were generally zzso with dose reduction or treatment zzso 

Whether the zzso were due to zzso of zzso or to zzso effects is zzso The unusual zzso and the lack of clinical activity led to zzso of zzso 

